Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs)

Leukemia Research

Volumn 34, Issue 9, 2010, Pages 1132-1138

  Kalle, Arunasree M ^a   Sachchidanand, Sachchidanand ^b   Pallu, Reddanna ^c  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b LUPIN LIMITED   (India)

^c UNIVERSITY OF HYDERABAD   (India)

Author keywords

Bax; Bcl2; COX 2; CREB; HDACs; Imatinib resistant K562 cells; MDR1

Indexed keywords

BCR ABL PROTEIN; CYCLIC AMP; CYCLOOXYGENASE 2; HISTONE DEACETYLASE; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PROSTAGLANDIN E2; PROTEIN KINASE C; SMALL INTERFERING RNA;

ARTICLE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 77955277307     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.030     Document Type: Article

References (42)

1. Le Coutre P., Tassi E., Varella-Garcia M., Barni R., Mologni L., Cabrita G., et al. Induction of resistance to the abelson inhibitor sti571 in human leukemic cells through gene amplification. Blood 2000, 95:1758-1766.
2. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to sti-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 2001, 293:876-880.
3. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple bcr-abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (sti571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
4. Nimmanapalli R., Bhalla K. Mechanisms of resistance to imatinib mesylate in bcr-abl-positive leukemias. Curr Opin Oncol 2002, 14:616-620.
5. Dai Y., Rahmani M., Corey S.J., Dent P., Grant S. A bcr/abl-independent, lyn-dependent form of imatinib mesylate (sti-571) resistance is associated with altered expression of bcl-2. J Biol Chem 2004, 279:34227-34239.
6. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., et al. Imatinib mesylate resistance through bcr-abl independence in chronic myelogenous leukemia. Cancer Res 2004, 64:672-677.
7. Yoshida C., Melo J.V. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol 2004, 79:420-433.
8. Arunasree K.M., Roy K.R., Anilkumar K., Aparna A., Reddy G.V., Reddanna P. Imatinib-resistant k562 cells are more sensitive to celecoxib, a selective cox-2 inhibitor: role of cox-2 and mdr-1. Leuk Res 2008, 32:855-864.
9. Sambrook J, Frotsch CF, Maniatis T. Molecular Cloning, CSHL Press, 1989.
10. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
11. Donze O., Picard D. Rna interference in mammalian cells using sirnas synthesized with t7 rna polymerase. Nucleic Acids Res 2002, 30:e46.
12. Milligan J.F., Uhlenbeck O.C. Synthesis of small rnas using t7 rna polymerase. Methods Enzymol 1989, 180:51-62.
13. Patel V.A., Dunn M.J., Sorokin A. Regulation of mdr-1 (p-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002, 277:38915-38920.
14. Roy K.R., Reddy G.V., Maitreyi L., Agarwal S., Achari C., Vali S., et al. Celecoxib inhibits mdr1 expression through cox-2-dependent mechanism in human hepatocellular carcinoma (hepg2) cell line. Cancer Chemother Pharmacol 2009.
15. Puhlmann U., Ziemann C., Ruedell G., Vorwerk H., Schaefer D., Langebrake C., et al. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic hl-60 cells. J Pharmacol Exp Ther 2005, 312:346-354.
16. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000, 275:20436-20443.
17. Kume S., Haneda M., Kanasaki K., Sugimoto T., Araki S., Isono M., et al. Silent information regulator 2 (sirt1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 2006, 40:2175-2182.
18. Chu F., Chou P.M., Zheng X., Mirkin B.L., Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005, 65:10183-10187.
19. Lee S.M., Bae J.H., Kim M.J., Lee H.S., Lee M.K., Chung B.S., et al. Bcr-abl-independent imatinib-resistant k562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 2007, 322:1084-1092.
20. Chambers A.E., Banerjee S., Chaplin T., Dunne J., Debernardi S., Joel S.P., et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 2003, 39:1165-1175.
21. Yoshida M. Chemical biology of hdac (histone deacetylase) inhibitors. Nippon Yakurigaku Zasshi 2008, 132:18-21.
22. Romanski A., Bacic B., Bug G., Pfeifer H., Gul H., Remiszewski S., et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 2004, 89:419-426.
23. Wendel H.G., de Stanchina E., Cepero E., Ray S., Emig M., Fridman J.S., et al. Loss of p53 impedes the antileukemic response to bcr-abl inhibition. Proc Natl Acad Sci USA 2006, 103:7444-7449.
24. Wang A.G., Kim S.U., Lee S.H., Kim S.K., Seo S.B., Yu D.Y., et al. Histone deacetylase 1 contributes to cell cycle and apoptosis. Biol Pharm Bull 2005, 28:1966-1970.
25. Duan H., Heckman C.A., Boxer L.M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005, 25:1608-1619.
26. Kikuchi H., Barman H.K., Nakayama M., Takami Y., Nakayama T. Participation of histones, histone modifying enzymes and histone chaperones in vertebrate cell functions. Subcell Biochem 2006, 40:225-243.
27. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11:1306-1313.
28. Lau L., Hansford L.M., Cheng L.S., Hang M., Baruchel S., Kaplan D.R., et al. Cyclooxygenase inhibitors modulate the p53/hdm2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 2007, 26:1920-1931.
29. Leung W.K., To K.F., Ng Y.P., Lee T.L., Lau J.Y., Chan F.K., et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001, 84:335-339.
30. Conkright M.D., Montminy M. Creb: the unindicted cancer co-conspirator. Trends Cell Biol 2005, 15:457-459.
31. Bito H., Takemoto-Kimura S. Ca(2+)/creb/cbp-dependent gene regulation: A shared mechanism critical in long-term synaptic plasticity and neuronal survival. Cell Calcium 2003, 34:425-430.
32. Ghosh R., Garcia G.E., Crosby K., Inoue H., Thompson I.M., Troyer D.A., et al. Regulation of cox-2 by cyclic amp response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia 2007, 9:893-899.
33. Crans-Vargas H.N., Landaw E.M., Bhatia S., Sandusky G., Moore T.B., Sakamoto K.M. Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. Blood 2002, 99:2617-2619.
34. Kinjo K., Sandoval S., Sakamoto K.M., Shankar D.B. The role of creb as a proto-oncogene in hematopoiesis. Cell Cycle 2005, 4:1134-1135.
35. Shankar D.B., Cheng J.C., Kinjo K., Federman N., Moore T.B., Gill A., et al. The role of creb as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005, 7:351-362.
36. Shankar D.B., Cheng J.C., Sakamoto K.M. Role of cyclic amp response element binding protein in human leukemias. Cancer 2005, 104:1819-1824.
37. Canettieri G., Morantte I., Guzman E., Asahara H., Herzig S., Anderson S.D., et al. Attenuation of a phosphorylation-dependent activator by an hdac-pp1 complex. Nat Struct Biol 2003, 10:175-181.
38. Yamaguchi K., Lantowski A., Dannenberg A.J., Subbaramaiah K. Histone deacetylase inhibitors suppress the induction of c-jun and its target genes including cox-2. J Biol Chem 2005, 280:32569-32577.
39. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., Craddock C., Turner B.M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759.
40. Giles F.J., Kantarjian H.M., Bekele B.N., Cortes J.E., Faderl S., Thomas D.A., Manshouri T., Rogers A., Keating M.J., Talpaz M., O'Brien S., Albitar M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 2002, 119:38-45.
41. Ziemann C., Schafer D., Rudell G., Kahl G.F., Hirsch-Ernst K.I. The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures. Hepatology 2002, 35:579-588.
42. Ratnasinghe D., Daschner P.J., Anver M.R., Kasprzak B.H., Taylor P.R., Yeh G.C., Tangrea J.A. Cyclooxygenase-2, p-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?. Anticancer Res 2001, 21:2141-2147.